Our data suggest that combining the already established clinical CRB-65 score with ET-1 significantly improves risk prediction in hospitalized COVID-19 patients regarding the composite endpoint “admission to intensive care unit or death within 28 days”. This evidence concerns the gene EDN1 and COVID-19.